OTLC · XBRL financial data

Oncotelic Therapeutics financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (OTLC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	1,741	—	—	70	—	—
Revenue from contracts with customers	1,741	—	—	—	—	—
Research and development	4,302	3,659	757	61	—	4
General and administrative	5,023	5,467	4,854	574	376	3,182
Total operating expenses	9,326	9,126	9,722	6,718	3,576	3,187
Operating income (loss)	(7,585)	(9,126)	(9,722)	(6,648)	(3,576)	(3,187)
Interest expense	1,998	2,003	2,971	1,045	—	—
Income tax expense (benefit)	—	—	—	—	—	111,550
Net income (loss)	(9,503)	(9,391)	5,095	(7,903)	(4,524)	249,280
Earnings per share, basic USD per share	(0.11)	(0.03)	0.01	(0.02)	(0.01)	0.59
Earnings per share, diluted USD per share	—	(0.03)	0.01	(0.02)	(0.01)	0.59
Weighted average shares, basic thousands of shares	88,100	303,079	384,075	396,166	404,396	421,046
Weighted average shares, diluted thousands of shares	—	303,079	457,300	396,166	404,396	422,235

Fiscal years (OTLC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	474	569	241	170	86	89
Accounts receivable	20	20	20	19	19	51
Prepaid and other current assets	—	—	—	—	9	1,038
Total current assets	616	627	303	272	134	1,198
Goodwill	21,062	21,062	12,071	5,988	2,788	2,788
Total assets	23,663	23,613	36,117	30,015	26,677	393,088
Accounts payable	1,937	1,928	1,736	—	—	—
Accrued liabilities	798	1,165	775	—	—	—
Total current liabilities	11,182	15,455	16,923	16,505	19,200	18,143
Total liabilities	—	—	16,923	18,403	19,200	131,357
Retained earnings (accumulated deficit)	(21,630)	(31,021)	(25,926)	(33,517)	(38,041)	211,239
Total stockholders' equity	11,772	7,956	19,409	12,130	8,252	262,761
Total liabilities and equity	23,663	23,613	36,117	30,015	26,677	393,088
Common shares outstanding (cover page) thousands of shares	91,259	378,630	392,872	399,684	408,292	444,197

Fiscal years (OTLC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(9,503)	(9,391)	5,095	(7,903)	(4,524)	249,280
Stock-based compensation	2,148	763	902	—	—	2,379
Net cash from operating activities	(2,812)	(4,434)	(1,453)	(1,321)	(740)	(1,383)
Proceeds from issuing common stock	—	420	159	—	—	—
Proceeds from long-term debt	250	—	—	—	—	—
Net cash from financing activities	3,224	4,529	1,125	1,250	656	1,386
Net change in cash	412	95	(327)	(71)	(84)	3

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Oncotelic Therapeutics	186	250	(92)*	457.5M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
TherapeuticsMD	9,189	not reported	not reported	11.6M	—	Q2 FY26 10-QJun 30, 2026
Artelo Biosciences	4,198	not reported	(5,033)*	4.6M	0.8 quarters	Q2 FY26 10-QJun 30, 2026
Bioxytran	177	not reported	(350)*	114.7M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Raphael Pharmaceutical	1	not reported	0*	20.2M	—	Q2 FY26 10-QJun 30, 2026
Alaunos Therapeutics	124	0	(300)*	2.5M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
GT Biopharma	4,960	not reported	(4,260)*	45.1M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
BioCardia	4,117	not reported	(1,735)*	15.1M	2.4 quarters	Q2 FY26 10-QJun 30, 2026
Traws Pharma	5,016	not reported	(7,504)*	15.4M	0.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.